In the present study, to assess the effectiveness of targeting IL-17A and IL-17F in treating systemic amyloidosis and arteriosclerosis, KCASP1Tg mice were cross-mated with IL-17A-, IL-17F-, and IL-17AF-deficient mice, and observed until late stage of dermatitis. This evidence concerns the gene IL17A and skin disorder.